Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Casp1i
- Development stage
- Preclinical
- Lead developer
- IPCURE
- Modality
- Small Molecules, Peptides
01
Overview
Casp1i is a discovery-stage small peptidomimetic inhibitor of caspase-1 (interleukin-1 converting enzyme) being developed by IPCURE. Caspase-1 is a cysteine protease that plays a critical role in the innate immune system by processing the inactive precursors of the inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18) into their active forms. It also mediates pyroptosis, a form of programmed cell death associated with inflammation. By utilizing a peptidomimetic scaffold, IPCURE aims to achieve potent and selective inhibition of caspase-1 to address various inflammatory and neurodegenerative pathologies. The drug is currently in the early discovery phase of development.
- Other names
- IPCURE Caspase-1 inhibitorIPCURE Caspase-1 peptidomimetic
02
Targets
CASP1 (Caspase-1)
Beyond the preview
Go deeper on Casp1i.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Casp1i.